Silver Book Fact

Gene transfer process treatment for diabetic retinopathy

A gene transfer process that produces a VEGF receptor prevents retinal vascular permeability (RVP) associated with diabetes that could have value in treating diabetic retinopathy.

Ramirez M, Wu Z, Moreno-Carranza B, Jeziorski M, et al. Vasoinhibin Gene Transfer by Adenoassociated Virus Type 2 Products Against VEGF-and Diabetes-Induced Retinal Vasopermeability. Invest Opthalmol Vis Sci. 2011; 52(12): 8944-8950. http://www.researchgate.net/publication/51720075_Vasoinhibin_Gene_Transfer_by_Adenoassociated_Virus_Type_2_Protects_against_VEGF-_and_Diabetes-Induced_Retinal_Vasopermeability

Reference

Title
Vasoinhibin Gene Transfer by Adenoassociated Virus Type 2 Products Against VEGF-and Diabetes-Induced Retinal Vasopermeability
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Ramirez M, Wu Z, Moreno-Carranza B, Jeziorski M, et al
Volume & Issue
Volume 52, Issue 12
Pages
8944-8950
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients…  
  • A study on the impact of diet on age-related macular degeneration (AMD) found that those who took the highest amounts of carotenoids, such as lutein and zeaxanthin, had a 43%…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Lucentis to treat wet age-related macular degeneration (AMD)
    An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25%…